Bioactive Products
| A unique collection of 674 anticancer natural compounds for high throughput screening (HTS) and New anticancer drug research | ||
| Catalog No: | B91 | Anticancer Compound Library Screening Details |
| Size: | 1mg/well * 674 Compounds 2mg/well * 674 Compounds | |
| Cat. No. | Information |
| CFN93368 | Escin IA Escin IA is a prodrug and its structure can be converted to desacylescin I by human intestinal bacteria and Lactobacillus brevis., desacylescin I as a biotransformation product shows potentially inhibitory effects on mouse tumor, and a potential candidate for anti tumor agents. Escin IA has anti-TNBC metastasis activity, and its action mechanisms involved inhibition of EMT process by down-regulating LOXL2 expression. |
| CFN90911 | Desoxyrhaponticin Desoxyrhaponticin is an agent that is potentially effective in controlling postprandial hyperglycemia in diabetes. Desoxyrhaponticin could be considered as a promising fatty acid synthase(FAS) inhibitor, it could inhibit intracellular FAS activity and downregulate FAS expression in human breast cancer MCF-7 cells. |
| CFN90916 | Tubeimoside III Tubeimoside III has anti-inflammatory, anti-tumor, and anti-tumorigenic activities, stronger than those of tubeimoside II. It has acute toxicity, stronger than that of tubeimoside II. |
| CFN90915 | Tubeimoside II Tubeimoside I, tubeimoside II, and tubeimoside III show anti-inflammatory, antitumor, and antitumor-promo ting effects. |
| CFN90886 | Irinotecan hydrochloride Irinotecan hydrochloride is a water soluble topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer. |
